Background:
Women with schizophrenia or other psychotic disorders differ from male patients in
many respects, including psychopathology, prognosis, disease course, and substance use
comorbidities. Most studies performed to date to investigate the association between
drug use and psychosis have not evaluated gender differences, although this has started
to change in recent years.
Methods:
We briefly summarize the available evidence on gender differences in drug use and
substance use disorders (SUD) in psychotic patients during the early phases of the
psychotic illness and during the course of schizophrenia.
Results:
Substance use and SUD are both less prevalent in women, both in the general
population and at all phases of the psychotic spectrum. Some studies suggest that SUD
may be underdiagnosed in female patients, in part due to their more vulnerable profile.
Substance use, especially cannabis, may more negatively impact females, especially on
the disease course and prognosis. The available data suggest that it may be more
difficult to treat SUD in female patients with schizophrenia, which could negatively
impact prognosis.
Conclusion:
Women with concomitant psychotic illness and SUD comprise a highly vulnerable
subgroup. This should be considered when selecting the treatment approach, especially
in the early phases of the illness, to ensure better outcomes.